TY - JOUR
T1 - Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer’s disease
AU - Cervellati, Carlo
AU - Trentini, Alessandro
AU - Rosta, Valentina
AU - Passaro, Angelina
AU - Bosi, Cristina
AU - Sanz, Juana Maria
AU - Bonazzi, Stefania
AU - Pacifico, Salvatore
AU - Seripa, Davide
AU - Valacchi, Giuseppe
AU - Guerini, Remo
AU - Zuliani, Giovanni
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Beta-secretase (BACE1) is a key enzyme in the formation of amyloid-β; its activity/concentration is increased in brain and cerebrospinal fluid of patients with late-onset Alzheimer’s disease (LOAD). Since BACE1 was found also in blood, we evaluated its potential as peripheral biomarker. To this aim, serum BACE1 activity was assessed in 115 subjects with LOAD and 151 controls. We found that BACE1 changed across groups (p < 0.001) with a 25% increase in LOAD versus controls. High levels of BACE1 (IV quartile) were independently associated with the diagnosis of LOAD (OR 2.8; 1.4–5.7). Diagnostic accuracy was 76% for LOAD. Our data suggest that increased BACE1 activity in serum may represent a potential biomarker for LOAD. Additional studies are needed to confirm the usefulness of BACE1, alone or in combination with other markers, in discriminating patients and predicting LOAD onset and progression.
AB - Beta-secretase (BACE1) is a key enzyme in the formation of amyloid-β; its activity/concentration is increased in brain and cerebrospinal fluid of patients with late-onset Alzheimer’s disease (LOAD). Since BACE1 was found also in blood, we evaluated its potential as peripheral biomarker. To this aim, serum BACE1 activity was assessed in 115 subjects with LOAD and 151 controls. We found that BACE1 changed across groups (p < 0.001) with a 25% increase in LOAD versus controls. High levels of BACE1 (IV quartile) were independently associated with the diagnosis of LOAD (OR 2.8; 1.4–5.7). Diagnostic accuracy was 76% for LOAD. Our data suggest that increased BACE1 activity in serum may represent a potential biomarker for LOAD. Additional studies are needed to confirm the usefulness of BACE1, alone or in combination with other markers, in discriminating patients and predicting LOAD onset and progression.
KW - BACE1
KW - Blood-based biomarkers
KW - Late-onset Alzheimer’s disease
KW - Mild cognitive impairment
KW - Mixed dementia
UR - http://www.scopus.com/inward/record.url?scp=85075261332&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075261332&partnerID=8YFLogxK
U2 - 10.1007/s11357-019-00127-6
DO - 10.1007/s11357-019-00127-6
M3 - Article
AN - SCOPUS:85075261332
JO - GeroScience
JF - GeroScience
SN - 2509-2715
ER -